Related Experiment Videos
A crossover study on lipid and weight changes associated with olanzapine and risperidone
Kuan-Pin Su1, Po-Lun Wu, Carmine M Pariante
1Department of General Psychiatry, China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan. cobol@www.cmuh.org.tw
Psychopharmacology
|October 22, 2005
Summary
Olanzapine use is linked to higher triglyceride levels and body weight compared to risperidone in schizophrenia patients. Close monitoring of metabolic changes during antipsychotic treatment is recommended.
Area of Science:
- Psychiatry
- Pharmacology
- Metabolic Medicine
Background:
- Previous studies suggest olanzapine may increase metabolic dysfunction risks more than risperidone.
- Crossover study designs minimize individual variations in metabolic profiles and lifestyle factors.
Purpose of the Study:
- To evaluate the comparative metabolic effects of olanzapine and risperidone.
- To assess changes in body weight, lipid profiles, and glucose levels after switching antipsychotic medications.
Main Methods:
- A crossover study involving 15 schizophrenic patients switching between olanzapine and risperidone.
- Assessment of body weight, lipid profiles (triglycerides, cholesterol, HDL, LDL), and fasting glucose before and 3 months after medication crossover.
Main Results:
- Switching to olanzapine significantly increased triglyceride levels and body weight.
- Switching to risperidone significantly decreased triglyceride levels, body weight, and BMI.
- Overall, olanzapine treatment was associated with significantly higher triglyceride levels, body weight, and BMI compared to risperidone.
Conclusions:
- Olanzapine is associated with elevated triglyceride levels and body weight compared to risperidone.
- Close monitoring of weight and lipid profiles is crucial for patients on atypical antipsychotics like olanzapine and risperidone.